Thrombosis And Hemostasis Biomarkers Global Market Report 2025

The thrombosis and hemostasis biomarkers market size is expected to see strong growth in the next few years. It will grow to $6.87 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. Factors fueling this projected growth include a surge in cases of stroke and ischemic events, heightened awareness of venous thromboembolism, an increased incidence of bleeding disorders like hemophilia, a growing number of surgical interventions, and expanding healthcare budgets. Notable trends anticipated during the forecast period include advancements in biomarker detection technologies, the development of ultra-sensitive assays for D-dimer and fibrinogen, the rise of point-of-care diagnostic tools, the integration of artificial intelligence for biomarker interpretation and forecasting, and increased automation in clinical laboratory testing.

The increasing demand for precise and targeted therapies is anticipated to drive the growth of the thrombosis and hemostasis biomarkers market in the coming years. These therapies are advanced treatment approaches that focus on the molecular and genetic characteristics of a patient’s disease, aiming to improve efficacy while minimizing side effects. The rise in demand stems from a deeper understanding of genetic and molecular variations in diseases, which allows for more individualized treatment, thereby enhancing therapeutic outcomes and reducing risks. This trend supports the thrombosis and hemostasis biomarkers market by facilitating the development of more accurate diagnostic tools that can identify specific biomarkers, leading to more effective and tailored treatments for clotting disorders. For example, in March 2024, Novotech, an Australia-based contract research organization (CRO), reported that 43% of the 217 FDA-approved oncology therapies by the end of 2023 are categorized as precision oncology treatments, with 78 of them incorporating DNA or Next Generation Sequencing (NGS)-detectable biomarkers. As a result, the growing demand for these targeted therapies is expected to fuel market expansion.

Companies in the thrombosis and hemostasis biomarkers market are increasingly developing advanced diagnostic solutions such as automated VWF activity assays to improve the accuracy and reliability of bleeding disorder testing. An automated VWF activity assay is a high-throughput laboratory test that employs techniques like immunoturbidimetry or chemiluminescence to evaluate the binding efficiency of von Willebrand factor (VWF) - a key glycoprotein involved in hemostasis - to platelet glycoprotein Ib. This is essential for diagnosing and monitoring von Willebrand disease. For instance, in October 2022, Siemens Healthineers, a Germany-based medical technology company, introduced the INNOVANCE VWF Ac assay, a fully automated test designed to enhance the precision of VWF activity measurement. Utilizing VWF:GPIbM technology, this assay directly evaluates platelet binding activity and offers improved sensitivity and accuracy over earlier methods. As VWF is a widely recognized biomarker associated with both bleeding and thrombosis, the new assay helps in identifying previously undetectable VWF variants, thus enhancing diagnostic capabilities for von Willebrand disease. Moreover, it aligns with the latest clinical guidelines from the American Society of Hematology (ASH), the International Society on Thrombosis and Hemostasis (ISTH), and the National Hemophilia Foundation (NHF), underscoring its importance in modern diagnostic practices.

In February 2024, Procuritas Capital Investors, a Sweden-based private equity firm, acquired Precision BioLogic (PBI) and Affinity Biologicals for an undisclosed amount. This strategic acquisition aims to strengthen Procuritas' presence in the growing thrombosis and hemostasis diagnostics market. Precision BioLogic, based in Canada, offers FDA-cleared reagents and plasma-based products, along with strong research and development capabilities. Affinity Biologicals, also based in Canada, specializes in manufacturing products used in thrombosis and hemostasis research and diagnostics, including custom assay services. The deal is expected to leverage the strengths of both companies to capitalize on global healthcare trends and expand Procuritas’ diagnostic portfolio.

Major players in the thrombosis and hemostasis biomarkers market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Becton, Dickinson and Company (BD), Mayo Clinic Laboratories, bioMérieux S.A., Beckman Coulter Inc., QuidelOrtho Corporation, Bio-Rad Laboratories Inc., Cincinnati Children's Hospital Medical Center, ARUP Laboratories, HORIBA Ltd., Werfen S.A., Pathkind Diagnostics Pvt. Ltd., Diagnostica Stago, Agilus Diagnostics, Helena Laboratories Corporations, Cleveland Clinic Laboratories, Diazyme Laboratories Inc., Biomedica Diagnostics Inc., Atlas Medical GmbH.

North America was the largest region in the thrombosis and hemostasis biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in thrombosis and hemostasis biomarkers report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the thrombosis and hemostasis biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The thrombosis and hemostasis biomarkers market consists of revenues earned by entities by providing services such as clinical laboratory testing services, patient risk assessment services, disease monitoring services, and research and development services. The market value includes the value of related goods sold by the service provider or included within the service offering. The thrombosis and hemostasis biomarkers market also includes sales of clot waveform analysis kits, microfluidic coagulation testing devices, and factor assay kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Thrombosis and hemostasis biomarkers are biological indicators that offer valuable insights into the mechanisms of blood clot formation and the regulation of bleeding. These biomarkers play a vital role in monitoring the equilibrium between clot development and its breakdown, serving as essential tools in evaluating vascular health and diagnosing coagulation-related disorders.

The primary products in the thrombosis and hemostasis biomarkers market include reagents and consumables as well as analyzers. Reagents and consumables encompass crucial chemical agents and disposable lab supplies - such as assay kits, buffers, calibrators, and control solutions - used for detecting, measuring, and analyzing biomarkers associated with clotting and bleeding conditions. These products are utilized in a variety of diagnostic tests, including D-dimer, anti-thrombin III, plasminogen, soluble fibrin, factor VIII, prothrombin (PT), activated partial thromboplastin time (APTT), and others. Their applications span across cardiovascular diseases, neurological disorders, cancer, pregnancy-related complications, and orthopedic surgeries. Key end users of these biomarkers include hospitals, diagnostic laboratories, pharmaceutical firms, academic research centers, and home healthcare providers.

The thrombosis and hemostasis biomarkers market size has grown strongly in recent years. It will grow from $4.8 billion in 2024 to $5.17 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. Growth during the historical period was driven by factors such as a rise in cardiovascular disease prevalence, an aging population, an increase in cancer-related thrombosis, a surge in obesity and sedentary behavior, as well as the growing burden of diabetes and metabolic disorders.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.